Zai Lab Ltd stock (US98887Q1040): analyst trims target after Q1 loss as oncology pipeline advances

Zai Lab Ltd opened 2026 with a challenging first quarter: revenue declined year over year and the company remained loss-making, which led CICC to lower its price target for the stock while maintaining an Outperform rating, according to a report summarized by AASTOCKS as of 05/13/2026. At the same time, Zai Lab continues to invest heavily in its oncology pipeline, including the antibody-drug conjugate candidate ZL-1310 that recently appeared in a regulatory round-up for extrapulmonary neuroendocrine carcinoma, as reported by BioWorld as of 05/19/2026.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

Zai Lab Ltd: core business model

Zai Lab focuses on discovering, developing and commercializing innovative medicines for oncology, autoimmune and infectious diseases, with an emphasis on bringing global therapies to patients in China and other Asian markets. The group combines in-licensed assets from international partners with internal research programs, aiming to accelerate development through localized clinical expertise and regulatory experience.

The company’s strategy blends two pillars: first, building a commercial portfolio of approved drugs in oncology and immunology that can generate near-term revenue, and second, advancing a deep pipeline of novel molecules, including antibody-drug conjugates and targeted therapies, to drive long-term growth. By co-developing products with multinational pharmaceutical firms, Zai Lab seeks to share development risks while retaining substantial economics in its home region.

In practice, this means Zai Lab often acquires rights to late-stage assets for Greater China or Asia-Pacific, conducts regional trials and navigates local regulatory pathways, while its partners lead global programs. At the same time, the company invests in early-stage research platforms to generate proprietary candidates such as ZL-1310, its DLL3-targeting antibody-drug conjugate for difficult-to-treat neuroendocrine tumors. This hybrid model is designed to balance pipeline optionality with a growing commercial base.

Main revenue and product drivers for Zai Lab Ltd

Zai Lab’s revenue currently stems mainly from sales of approved oncology and immunology medicines in China, complemented by collaboration and licensing income. According to a CICC summary reported by AASTOCKS as of 05/13/2026, the company generated approximately USD 99.6 million in revenue in the first quarter of 2026, a decrease of about 6% year over year. The same report indicated a net loss of around USD 51 million for the period, highlighting that the business remains in investment mode.

The top line is largely influenced by the uptake of key oncology brands, which are competing in crowded markets but benefit from rising diagnosis rates and improved access to innovative therapies in China. Pricing dynamics, reimbursement decisions and competitive launches can all move revenue meaningfully from quarter to quarter. In addition, milestone payments from global partners—tied to regulatory approvals or development progress—can intermittently boost reported revenue, making quarterly figures somewhat volatile.

On the cost side, research and development spending is substantial given the breadth of Zai Lab’s pipeline. Clinical trial expenses, manufacturing scale-up and commercialization costs for recently launched drugs all weigh on profitability. The net loss reported for the first quarter of 2026 illustrates that the company continues to prioritize pipeline and market expansion over near-term earnings, a common pattern among mid-cap biotech companies seeking to build a diversified portfolio.

First-quarter 2026 results and CICC rating update

The first-quarter 2026 earnings release marked an important reference point for investors tracking Zai Lab’s progress. As summarized by CICC in a note reported via AASTOCKS as of 05/13/2026, revenue reached approximately USD 99.6 million, down about 6% compared with the same quarter a year earlier. While this topline pressure reflected product dynamics and the timing of collaboration income, the brokerage described the results as broadly in line with its expectations.

Despite the revenue decline, CICC maintained its Outperform rating on the Hong Kong-listed shares and the US-listed ADSs but trimmed its price targets. According to the same report, the bank used a discounted cash flow model to lower the H-share target price by roughly 8% to HKD 20.2 and the US ADS target to USD 26. This adjustment reflects updated assumptions on revenue growth, margins and risk, yet signals that the brokerage still sees upside potential over its investment horizon.

The quarter also underscored ongoing losses. CICC quoted a net loss of about USD 51 million for Zai Lab in the first three months of 2026, indicating that operating leverage has not yet offset R&D and commercialization costs. For investors, this combination of negative earnings and a recalibrated—but still positive—analyst stance may reinforce the view that the stock’s trajectory is closely tied to clinical and regulatory milestones rather than near-term profitability metrics.

Pipeline spotlight: ZL-1310 and oncology innovation

On the pipeline front, Zai Lab is pursuing multiple oncology candidates, with antibody-drug conjugates standing out as a strategic focus area worldwide. One of the company’s notable programs is zocilurtatug pelitecan, also known as ZL-1310, a DLL3-targeting antibody-drug conjugate developed together with Zymeworks. This asset is being investigated for extrapulmonary neuroendocrine carcinoma, an aggressive cancer type with limited current treatment options, according to coverage from BioWorld as of 05/19/2026.

DLL3 has emerged as a promising target in certain neuroendocrine tumors because it tends to be overexpressed on malignant cells while showing limited expression in normal tissues. Antibody-drug conjugates directed at DLL3 aim to deliver cytotoxic payloads directly to cancer cells, potentially improving efficacy and limiting systemic toxicity. Zai Lab’s ZL-1310 program is currently in phase I/II studies for later-line extrapulmonary neuroendocrine carcinoma, as noted in an industry overview on antibody-drug conjugate programs referenced by AllSci as of 05/10/2026.

While early-stage clinical results have not yet been detailed in depth in mainstream financial reports, the progression of ZL-1310 and similar oncology programs represents an important long-term value driver for Zai Lab. Positive safety and efficacy signals could support future regulatory submissions and potential commercialization in both Asian and Western markets, whereas setbacks would likely require strategic adjustments and could affect investor sentiment. For now, the inclusion of ZL-1310 in regulatory and industry round-ups underlines that the asset is moving forward in the clinic.

Capital markets signals: changes in major shareholdings

Alongside earnings and pipeline news, changes in institutional shareholdings can offer clues about how large investors view Zai Lab’s risk-reward profile. A recent filing at the Hong Kong Stock Exchange indicated that Goldman Sachs Group reduced its long position in Zai Lab’s Hong Kong-listed shares on May 14, 2026, according to a brief report carried on Reuters via TradingView as of 05/19/2026.

The filing did not provide a qualitative assessment from Goldman Sachs on the company’s fundamentals, but such stake adjustments can result from internal risk management, portfolio rebalancing or changes in house views. For US investors following the Nasdaq-listed ADSs, the move is one data point within a broader mosaic of institutional positioning, which may also include other global asset managers that are not required to disclose every incremental change in holdings in real time.

It is important to note that a single institution trimming its stake does not necessarily signal a broad consensus shift. Instead, investors typically look for patterns across multiple filings and trading days, cross-referencing them with events such as earnings releases, analyst rating changes or clinical trial updates. In the case of Zai Lab, recent developments—ranging from the first-quarter loss to ongoing oncology trials—provide several possible catalysts that could influence institutional strategies.

Why Zai Lab Ltd matters for US investors

For US-based investors, Zai Lab offers exposure to the intersection of China’s healthcare growth story and global oncology innovation through its Nasdaq-listed American depositary shares. The company’s footprint in both Shanghai and Cambridge, Massachusetts connects it to major hubs for clinical research and biotech financing, positioning it as a cross-border player within the sector.

Given that the United States remains the world’s largest market for prescription drugs, Zai Lab’s partnerships and co-development arrangements with Western biopharma companies can be particularly relevant. Successful late-stage trials could open the door to regulatory submissions to the US Food and Drug Administration, enabling revenue streams in the US market either directly or via royalty-bearing deals. Conversely, increased regulatory scrutiny or geopolitical tensions could complicate cross-border collaboration and technology transfer.

From a portfolio construction perspective, the stock may be viewed as a niche healthcare holding with specific risks distinct from diversified US pharma majors. Its performance tends to be more sensitive to clinical readouts, China-specific policy changes and currency movements between the US dollar and the renminbi. As such, investors often treat Zai Lab as a satellite position within a broader healthcare allocation, using it to gain targeted exposure to Asian oncology opportunities.

Conclusion

Zai Lab Ltd is navigating a familiar biotech trade-off: near-term revenue softness and continued net losses versus a maturing commercial franchise and a pipeline with meaningful, but uncertain, upside. The first-quarter 2026 figures, featuring a roughly 6% year-on-year revenue decline to about USD 99.6 million and a net loss near USD 51 million, show that the path to sustained profitability remains a work in progress, as highlighted by CICC’s updated valuation reported by AASTOCKS as of 05/13/2026. At the same time, programs like the DLL3-targeting antibody-drug conjugate ZL-1310 underscore the company’s ambition to play a role in next-generation oncology therapies, a direction noted in sector coverage from BioWorld as of 05/19/2026. For investors, Zai Lab remains a story driven by clinical data, regulatory outcomes and strategic execution across both Chinese and global markets, with volatility likely as new information emerges.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

en | US98887Q1040 | ZLAB | boerse | 69376598 | bgmi